Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220213 · ClinicalTrials.gov registry record · NA
FELLAShip to Better Health
A NA study of Obesity & Overweight and Diabetes Type 2, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07220213: Recruiting NA study of Obesity & Overweight and Diabetes Type 2, sponsored by University of Alabama at Birmingham.
NCT07220213 is a NA study of Obesity & Overweight and Diabetes Type 2 that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 90 participants, below the 112-participant average among 28 other Obesity & Overweight trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220213, a NA study of Obesity & Overweight and Diabetes Type 2, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the FELLAship program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the FELLAship program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Primary Outcome
Change from baseline in the Life's Essential 8 overall cardiovascular health score (range 0-100, higher scores indicate better cardiovascular health), assessed at 12 and 24 weeks.
Conditions Studied
Interventions
- BEHAVIORAL FELLAship
Study Locations (1)
Alabama
- The Worship Center Cristian Church - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
What NCT07220213 shows while recruiting
NCT07220213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 112-participant average among 28 other Obesity & Overweight trials with a reported enrollment target (20% lower).
The record links to 6 conditions, with Obesity & Overweight appearing as the primary indexed condition, and to 1 intervention - of which FELLAship is the first listed.
NCT07220213 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT07220213 about?
NCT07220213 is a clinical study titled "FELLAShip to Better Health". The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aim...
What is the current status of trial NCT07220213?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2026-01-01. Estimated completion is 2027-01-01.
What conditions does trial NCT07220213 study?
This clinical trial studies the following conditions: Obesity & Overweight, Diabetes Type 2, Blood Sugar; High, High Cholesterol, High Cholesterol/Hyperlipidemia.
What interventions are being tested in trial NCT07220213?
The interventions under investigation include: FELLAship (BEHAVIORAL).
Who is sponsoring clinical trial NCT07220213?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220213 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity & Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220213's enrollment target sits among peer trials
90 13th of 28 higher than 16 of 28 other Obesity & Overweight trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity & Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity
RECRUITING · NA
-
Microrandomized Trial to Optimize Use of Burden-reducing Self-monitoring Approaches in Behavioral Obesity Treatment
RECRUITING · NA
-
Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy
RECRUITING · NA
-
Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults
RECRUITING · NA
-
Feasibility and Acceptability of a Pediatric Referral to Summer Day Camps to Treat Obesity in Children From Low-Income Households
RECRUITING · NA
-
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI